{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:47:10Z","timestamp":1788875230728,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Antiphospholipid syndrome (APS) is an acquired hypercoagulable condition associated with antiphospholipid antibody (aPL) presence. Data on re-thrombosis following APS-diagnosis are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective analysis of new thrombotic events among primary APS (pAPS) patients followed for up to 15 years in three medical centers in Israel.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 312 primary-APS patients, 143 (46%) had new thrombotic event classified to three patterns: (1)<jats:italic>Arterial\u2014<\/jats:italic>associated with heart valve disease (OR 7.24, 95% C.I. 2.26\u201324.6), hypertension (OR 3, 95% C.I. 1.44\u20136.25), elevated anti-B2-GPI IgM (OR 1.04, 95% C.I. 0.996\u20131.08), arterial thrombosis at presentation (OR 1.74 95% C.I. 0.992\u20133.26), and older age (41 vs. 34 years, p &amp;lt; 0.001). (2)<jats:italic>Venous\u2014<\/jats:italic>linked with venous thrombosis at presentation (OR 12.9, 95% C.I. 5.27\u201331.6, p &amp;lt; 0.001), heart valve disease (OR 9.81 95% C.I. 1.82\u201352.9, p = 0.018), aGAPSS (OR 1.15 95% C.I. 1.02\u20131.29), and younger age (31 vs. 36.5 years, p = 0.001); and (3)<jats:italic>Combined pattern<\/jats:italic>\u2014associated with heart valve disease (OR 40.5 95% C.I. 7.7\u2013212) and pulmonary embolism (OR 7.47 95% C.I. 1.96\u201328.5). A 4th variant \u201cthe Breakthrough pattern\u201d defined by re-thrombosis despite prophylactic therapy was observed in 100\/143 (70%) patients and linked with heart valve disease (OR 8. 95% C.I. 2.43\u201326.3), venous thrombosis at presentation (OR 2.61 95% C.I. 1.47\u20134.66), leg ulcers (OR 12.2, 95% C.I. 1.4\u2013107), hypertension (OR 1.99, 95% C.I. 0.92\u20134.34), and higher aGAPSS (OR 1.08, 95% C.I. 0.99\u20131.18).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this real-life observation, re-thrombosis was common among pAPS patients including in those recommended to receive prophylactic therapy. Different patterns of recurrence were identified and linked with presenting symptoms, specific serological markers, APS manifestations, and comorbidities. Studies that will address interventions to prevent recurrences of APS-related events are needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.843718","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T15:21:38Z","timestamp":1650381698000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome\u2014Multicenter, Real-Life Long-Term Follow-Up"],"prefix":"10.3389","volume":"13","author":[{"given":"Stanley","family":"Niznik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha J.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Avnery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aharon","family":"Lubetsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soad","family":"Haj Yahia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Agmon-Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost JTH"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310395051","article-title":"Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-Criteria APS Manifestations (I): Catastrophic APS, APS Nephropathy and Heart Valve Lesions","volume":"20","author":"Cervera","year":"2011","journal-title":"Lupus"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic Antiphospholipid Syndrome (CAPS): Descriptive Analysis of 500 Patients From the International CAPS Registry","volume":"15","author":"Rodr\u00edguez-Pint\u00f3","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B4","article-title":"EULAR Recommendations for the Management of Antiphospholipid Syndrome in Adults","volume":"78","author":"Tektonidou","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161364","article-title":"Longterm Outcome of Patients With Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study","volume":"44","author":"Taraborelli","year":"2017","journal-title":"J Rheumatol"},{"key":"B6","article-title":"Primary Antiphospholipid Syndrome: Functional Outcome After 10 Years","volume":"27","author":"Erkan","year":"2000","journal-title":"J Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000170645.40562.09","article-title":"Thrombotic Risk Factors In Primary Antiphospholipid Syndrome: A 5-Year Prospective Study","volume":"36","author":"Turiel","year":"2005","journal-title":"Stroke"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical Course of High-Risk Patients Diagnosed With Antiphospholipid Syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017008185","article-title":"Recurrent Thrombosis in Patients With Antiphospholipid Antibodies and Arterial Thrombosis on Antithrombotic Therapy","volume":"1","author":"Jackson","year":"2017","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: The Global Anti-Phospholipid Syndrome Score","volume":"52","author":"Sciascia","year":"2013","journal-title":"Rheumatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.02.155","article-title":"The Adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for Risk Stratification in Young APS Patients With Acute Myocardial Infarction","volume":"240","author":"Radin","year":"2017","journal-title":"Int J Cardiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus Anticoagulants are Stronger Risk Factors for Thrombosis Than Anticardiolipin Antibodies in the Antiphospholipid Syndrome: A Systematic Review of the Literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.04.009","article-title":"The Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) and the Risk of Recurrent Thrombosis: Results From the APS ACTION Cohort","volume":"49","author":"Radin","year":"2019","journal-title":"Semin Arthritis Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1304720","article-title":"Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome","volume":"38","author":"Les","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.04.009","article-title":"Increased Risk of Thrombosis in Antiphospholipid Syndrome Patients Treated With Direct Oral Anticoagulants. Results from an international patient-level data meta-analysis","volume":"17","author":"Dufrost","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473","article-title":"Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649988","article-title":"Laboratory Identification of Lupus Anticoagulants: Results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants\/Antiphospholipid Antibodies of the ISTH","volume":"74","author":"Brandt","year":"1995","journal-title":"Thromb Haemost"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317703493","article-title":"Independent Validation of the Adjusted GAPSS: Role of Thrombotic Risk Assessment in the Real-Life Setting","volume":"26","author":"Fernandez Mosteirin","year":"2017","journal-title":"Lupus"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and Mortality in the Antiphospholipid Syndrome During a 10-Year Period: A Multicentre Prospective Study of 1000 Patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110800","article-title":"Morbidity, Mortality, and Organ Damage in Patients With Antiphospholipid Syndrome","volume":"39","author":"Grika","year":"2012","journal-title":"J Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315617538","article-title":"Patients With Antiphosholipid Syndrome and Thrombotic Recurrences: A Real World Observation (the Piedmont Cohort Study)","volume":"25","author":"Bazzan","year":"2016","journal-title":"Lupus"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310395803","article-title":"Evidence-Based Recommendations for the Prevention and Long-Term Management of Thrombosis in Antiphospholipid Antibody-Positive Patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies","volume":"20","author":"Ruiz-Irastorza","year":"2011","journal-title":"Lupus"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.02.003","article-title":"The Treatment of Anti-Phospholipid Syndrome: A Comprehensive Clinical Approach","volume":"90","author":"Chighizola","year":"2018","journal-title":"J Autoimmun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)00060-5","article-title":"Natural History and Risk Factors for Thrombosis in 360 Patients With Antiphospholipid Antibodies: A Four-Year Prospective Study From the Italian Registry","volume":"100","author":"Finazzi","year":"1996","journal-title":"Am J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-4-303","article-title":"Antiphospholipid Thrombosis: Clinical Course After the First Thrombotic Event in 70 Patients","volume":"117","author":"Rosove","year":"1992","journal-title":"Ann Intern Med"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1111\/1471-0528.15469","article-title":"Factors Associated With First Thrombosis in Patients Presenting With Obstetric Antiphospholipid Syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: A Retrospective Study","volume":"126","author":"de Jes\u00fas","year":"2019","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-017-8899-x","article-title":"Anti-Mutated Citrullinated Vimentin Antibodies in Antiphospholipid Syndrome: Diagnostic Value and Relationship With Clinical Features","volume":"65","author":"Alessandri","year":"2017","journal-title":"Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13317-020-00131-3","article-title":"Profiles of Criteria and non-Criteria Anti-Phospholipid Autoantibodies are Associated With Clinical Phenotypes of the Antiphospholipid Syndrome","volume":"11","author":"Volkov","year":"2020","journal-title":"Auto- Immun Highlights"},{"key":"B30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0301-2115(00)00404-8","article-title":"Antiphospholipid Syndrome and Recurrent Miscarriages","volume":"96","author":"Vinatier","year":"2001","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B31","article-title":"Incidence of Anticardiolipin Antibodies and Lupus Anticoagulant Factor Among Women Experiencing Unexplained Recurrent Abortion and Intrauterine Fetal Death","volume":"8","author":"Al Jameil","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.023021","article-title":"Antiphospholipid Syndrome With Isolated Isotype M Anticardiolipin and\/or Anti-B2GPI Antibody Is Associated With Stroke","volume":"49","author":"Urbanski","year":"2018","journal-title":"Stroke"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.10.010","article-title":"Thrombotic Antiphospholipid Syndrome: A Practical Guide to Diagnosis and Management","volume":"198","author":"Sayar","year":"2021","journal-title":"Thromb Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"102491","DOI":"10.1016\/j.autrev.2020.102491","article-title":"The Effect of Hydroxychloroquine on Thrombosis Prevention and Antiphospholipid Antibody Levels in Primary Antiphospholipid Syndrome: A Pilot Open Label Randomized Prospective Study","volume":"19","author":"Kravvariti","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-eurolupus.12","article-title":"Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicentre Israeli Experience","volume":"39","author":"Agmon-Levin","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504133321504","article-title":"The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome","volume":"332","author":"Khamashta","year":"1995","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7326\/M21-1094","article-title":"Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism","volume":"174","author":"Khan","year":"2021","journal-title":"Ann Intern Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.11.007","article-title":"Thrombotic Recurrences and Bleeding Events in APS Vascular Patients: A Review From the Literature and a Comparison With the APS Piedmont Cohort","volume":"12","author":"Bazzan","year":"2013","journal-title":"Autoimmun Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.843718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T05:30:35Z","timestamp":1700458235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.843718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2022.843718"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.843718","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"article-number":"843718"}}